Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics

Eli Lilly controls roughly 60% of the U.S. weight-loss drug market and its tirzepatide products (Mounjaro and Zepbound) posted triple-digit revenue growth last quarter; Lilly shares are down ~8% YTD and trade at ~28x forward earnings (recently >31x). Viking Therapeutics plans to advance oral VK2735 to phase 3 in Q3 while its injectable phase 3 is ongoing; Viking stock is +2% YTD and +16% over the past year. A regulatory decision on Lilly’s oral weight-loss candidate in the coming weeks is a near-term catalyst, while Viking represents a higher-risk, pre-revenue competitor with strong trial data.

Analysis

The market is bifurcating into (1) scaled incumbents that monetize at the point of care and through payer contracts, and (2) small-cap clinical-stage players that compete on marginal efficacy signals. That split creates asymmetric second-order winners: fill/finish CMOs, specialty pharmacy networks, and pen/syringe manufacturers gain pricing power and bargaining leverage as new entrants strain incumbent supply lines; conversely, late-stage biotechs face a commercialization cliff even after positive P2 because distribution and contracting are a 12–36 month TTM problem.

Regulatory and payer dynamics are the dominant short-term catalysts. A regulatory decision on an oral entrant in the coming weeks can reprice leaders within days; class-level safety signals or formal payer step edits could compress realized price by 20–40% over 3–12 months, rapidly reversing market share gains. For small caps, moving from P2 to a P3 start (Q3) is de-risking but still binary — commercial runway and manufacturing scale are the bigger multi-year constraints.

Viking’s profile is a classic binary option on clinical readouts plus optionality from an amylin/calcitonin program. If phase 3 initiation and subsequent readouts validate efficacy comparable to leaders, the stock could re-rate materially, but failure or safety noise would erase value faster than incumbents can be dislodged. Investors should price in probability-weighted timelines: regulatory/cost negotiation outcomes in 0–6 months for incumbents, and 12–36+ months for biotech commercialization and market-share capture.

From a portfolio construction view, incumbent names are tradeable event exposures (approval/regulatory windows) with lower binary risk; small-cap biotechs are asymmetric high-volatility plays best sized as option-like allocations and hedged against class/regulatory drawdowns.

Key Decisions for Investors

• LLY – Tactical long ahead of regulator decision: initiate a 4–8% portfolio weight in equity or buy-to-open 9–12 month calls (delta ~0.40) and hedge with a 3–6 month 5–10% OTM put. Timeframe: immediate to 3 months around approval window. Risk/Reward: 20–40% upside on positive approval/pricing announcement vs capped downside (~8–12%) with put hedge.
• VKTX – Small, option-like exposure: allocate 0.5–1.5% of portfolio to VKTX common or buy Jan-2028 LEAP calls (to limit cash loss) ahead of Q3 phase‑3 start. Timeframe: 12–24 months for readouts. Risk/Reward: binary 3x–5x upside on positive efficacy and clean safety vs high probability of 50–70% drawdown on adverse outcome; hard stop at -30% of position value.
• Pair trade – Hedge class/regulatory risk: long VKTX (small) paired with short a biotech ETF or small-cap biotech basket (e.g., IBB exposure via puts) sized to neutralize class-wide drawdowns. Timeframe: 6–24 months. Risk/Reward: preserves upside to idiosyncratic VKTX success while limiting exposure to negative GLP‑1 class headlines that would hit all names.
• Supply-chain arbitrage – Long suppliers to incumbents: selectively add exposure to large-scale peptide CMOs or specialty pharmacy operators (size 2–4%); these names should see revenue leverage if demand remains supply-constrained. Timeframe: 3–12 months. Risk/Reward: lower volatility exposure with 15–25% upside on sustained demand vs execution/contract risk.